| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 2 |
| Top 5 Target | Count |
|---|---|
| APP x DYRK1A x LOXL2 x α-synuclein | 1 |
| Mitochondrial proteins | 1 |
Mechanism APP inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Mitochondrial proteins inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2025 |
Sponsor / Collaborator |
Start Date20 Jan 2025 |
Sponsor / Collaborator |
Start Date28 Oct 2024 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
(+)-Epicatechin ( Mitochondrial proteins ) | Radiodermatitis More | Phase 3 |
(-)-Epigallocatechin Gallate ( APP x DYRK1A x LOXL2 x α-synuclein ) | Radiodermatitis More | Phase 3 |





